(Q45252656)

11 December 2017

title

Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors (English)

1 reference

11 December 2017

1 reference

Asad Mian

1

1 reference

11 December 2017

Margaretha Guenther

2

1 reference

11 December 2017

Milton Finegold

3

1 reference

11 December 2017

Philip Ng

4

1 reference

11 December 2017

John Rodgers

5

1 reference

11 December 2017

Brendan Lee

6

1 reference

11 December 2017

publication date

29 December 2004

1 reference

Molecular Genetics and Metabolism

11 December 2017

published in

1 reference

11 December 2017

volume

84

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

278-288

1 reference

Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Evolution of adenoviruses as gene therapy vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Reports of adenovector "death" are greatly exaggerated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Generation of helper-dependent adenoviral vectors by homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Persistence in muscle of an adenoviral vector that lacks all viral genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.11.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2004.11.005

1 reference

11 December 2017

1 reference